Design and psychometric evaluation of the Quality of Life in patients with Anal Fistula Questionnaire by Ferrer-Márquez, Manuel et al.
	 1	
  
Design and psychometric evaluation of the ‘Quality of Life in patients with Anal 
Fistula Questionnaire’ (QoLAF-Q). 
REFERENCE: Ferrer-Márquez M, Espínola-Cortés N, Reina-Duarte A, Granero-
Molina J, Fernández-Sola C, Hernández-Padilla JM. Design and Psychometric 
Evaluation of the Quality of Life in Patients With Anal Fistula Questionnaire. Dis 
Colon Rectum 2017; 60: 1081–1089. 
Manuel Ferrer-Márquez1 (MD, PhD, MS); Natalia Espínola-Cortés2 (MD, MS); Angel 
Reina-Duarte3 (MD, PhD); José Granero-Molina4-5 (PhD, RN); Cayetano Fernández-
Sola5-6 (PhD, RN); José Manuel Hernández-Padilla7 (PhD, MSc, RN) 
1Surgeon. Departamento de Cirugía Colorectal. Servicio de Cirugía General y 
Digestiva. Hospital Torrecárdenas. Paraje de Torrecárdenas s/n. Almería. CP: 04009. 
Spain. 
2Resident in General Surgery. Departamento de Cirugía Colorectal. Servicio de Cirugía 
General y Digestiva. Hospital Torrecárdenas. Paraje de Torrecárdenas s/n. Almería. CP: 
04009. Spain. 
3Head of Department. Departamento de Cirugía Colorectal. Servicio de Cirugía General 
y Digestiva. Hospital Torrecárdenas. Paraje de Torrecárdenas s/n. Almería. CP: 04009. 
Spain. 
4Principal Lecturer. Nursing, Physiotherapy and Medicine Department. Faculty of 
Health Sciences. University of Almeria. Spain. Postal address: Universidad de Almería. 
Edificio de Ciencias de la Salud. Carretera de Sacramento s/n. Almería. CP: 04120. 
Spain. 
5Associate Researcher. Faculty of Health Sciences. Universidad Autónoma de Chile. 
Temuco. Chile. 
6Head of Department. Nursing, Physiotherapy and Medicine Department. Faculty of 
Health Sciences. University of Almeria. Spain. Postal address: Universidad de Almería. 
Edificio de Ciencias de la Salud. Carretera de Sacramento s/n. Almería. CP: 04120. 
Spain. 
7Lecturer. Adult, Child and Midwifery Department. School of Health and Education. 
Middlesex University. Hendon Campus. The Burroughs. NW4 4BT. London. United 
Kingdom. 
 
 
 
	 2	
Abstract 
Background: Quality of life is often considered when deciding and evaluating the 
treatment strategy for patients diagnosed with anal fistula. 
Objective: To develop and psychometrically test the ‘Quality of Life in patients with Anal 
Fistula Questionnaire’. 
Design: Observational cross-sectional study for the development and validation of a 
psychometric tool. 
Setting: General hospital in the southeast of Spain. 
Patients: Convenience sample of 54 patients diagnosed with anal fistula. 
Main outcomes measures: The tool’s reliability was assessed through its internal 
consistency (Cronbach’s α) and temporal stability (Spearman’s correlation coefficient (r) 
between test-retest). The content validity index of the items and the scale was calculated. 
Correlation analysis and an ordinal regression analysis between the developed tool and the 
SF-12 examined its concurrent validity. Principal component analysis and known-group 
analysis using Kruskal-Wallis Test examined its construct validity. 
Results: The reliability of the developed questionnaire was very high (α=0.908; r=0.861; 
p<0.01). Its content validity was excellent (all items’ content validity index=0.79–1; 
scale’s validity index=0.92). Evidence of its concurrent validity includes: [1] strong 
correlation between the developed tool and SF-12 (r=0.734; p<0.001), and [2] participants’ 
scores on the developed tool explained approximately 46.2% of the between-subject 
variation for the participants’ scores on the SF-12 (Nagelkerke-R2=0.462). Confirming its 
construct validity, principal component analysis revealed that two factors explained 
81.63% of the total variance found. Known-group analysis evidenced the questionnaire’s 
ability to detect expected differences in patients presenting with different symptomatology. 
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Limitations: The major limitations of this study were: using a small sample of Spanish-
speaking patients, not including patients in the initial development of the questionnaire, 
and developing the scoring system using a summation method.  
Conclusion: The ‘Quality of Life in patients with Anal Fistula Questionnaire’ has proven 
to be a valid, reliable and concise tool that could contribute to the evaluation of quality of 
life amongst patients with an anal fistula. 
Keywords 
Quality of life; anal fistula; psychometrics; validity; reliability. 
Introduction 
An anal fistula (AF) is an abnormal tract or cavity communicating with the rectum or 
anal canal by an identifiable internal opening.1-2 Most anal fistulae are believed to arise as 
a result of a cryptoglandular infection and are more frequent amongst adults between 30-60 
years old.2-3 Although the actual incidence of AF remains unknown and there is high 
geographical variability reported in the literature (from 0.86 per 10,000/year in Helsinki to 
2.32 per 10,000/year in Italy), this is generally considered an uncommon disease.3-4 
Nonetheless, the management of anal fistulae is often the focus in international literature 
on coloproctology. The symptomatology most frequently associated with an AF includes 
suppuration, bleeding and/or pain, which are often preceded by the drainage of a perianal 
abscess and can severely affect patients’ quality of life (QoL).2,5-6 The curative treatment 
for anal fistulae can be costly and always require a surgical intervention.3,7-8 Indeed, it is 
suggested that between 10-30% of the total surgical procedures performed by 
coloproctology specialists could be related to the management of anal fistulae.7   
Although the aim of undertaking surgery on these patients is clearly directed towards 
removing the fistula, alleviating its symptoms, preventing its recurrence, and preserving 
the sphincter’s function, its effectiveness can be variable.7 For example, in patients 
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presented with non-complex, primary fistulae (i.e. intersphicteric and low 
transsphincteric), fistulotomy is usually the surgical procedure of choice and is believed to 
be useful in around 90% of the cases.7,9-10 However, in patients presented with complex 
anal fistulae, the results from performing different surgical procedures (i.e. mucosal 
advancement flap, seton placement, LIFT procedure, plugs and adhesives, etc) remain 
unclear and are somewhat controversial.11-14 Consequently, a risk of recurrence of 
approximately 10-60%, and complications such as incontinence due to undergoing 
numerous unsuccessful surgical interventions can also contribute to negatively affect 
patients’ QoL.4,13-15 
In the light of this, patient QoL emerges as an important indicator that is often taken 
into consideration by coloproctology specialists when making individualised decisions on 
the treatment strategy to be followed for each patient and the posterior evaluation of its 
success.16-21 However, to the best of our knowledge, no instrument to specifically assess 
QoL in patients diagnosed with AF has been developed, validated and published. In fact, 
our literature review evidenced that the tools used to evaluate QoL amongst patients 
diagnosed with AF were initially designed for measuring either general health-related QoL 
(SF-12, SF-36)16-19 or other constructs related to patients’ incontinence (St Mark´s 
Incontinence Score, Cleveland Incontinence Score, Wexner Score and FIQL).16-21 In this 
context, the design of a valid and reliable instrument that aims to evaluate QoL amongst 
patients with AF could help to provide more specific and better-fitted information about 
this particular population.  
The aim of this study is to develop and evaluate the psychometric properties of a 
questionnaire to assess QoL in patients diagnosed with AF. 
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Methods 
Study design and participants 
In this study, an observational cross-sectional design was used for the 
development and validation of the ‘Quality of Life in patients with Anal Fistula 
Questionnaire’ (QoLAF-Q). Following a convenience sampling technique, patients 
attending the coloproctology clinic in a general hospital in the southeast of Spain 
between March 2015 and June 2016 were recruited for the study. The inclusion criteria 
for participation were: to be ≥18 years old and to have been diagnosed with a 
cryptoglandular AF. The exclusion criteria for participation were: to suffer any 
cognitive impairment that could interfere with understanding and completing the 
questionnaire, to suffer from inflammatory bowel disease or any other medical 
condition that could affect QoL (i.e. COPD, fibromyalgia…), and to present with an AF 
secondary to carcinoma, radiation therapy, obstetric damage or any other primary cause 
that could affect QoL. Eighty participants were eligible for inclusion and 54 volunteered 
to participate. Patient demographic characteristics, past medical history and information 
about the AF were collected. 
Ethical considerations 
The institutional ‘Ethics in Research Board’ granted ethical approval. Patients 
meeting the eligibility criteria were invited to participate in the study by their surgeon 
and received a written document with information about their rights, the study’s aim 
and the research plan. Patients who volunteered to participate signed an informed 
consent form before enrolling in the study. All data collected were treated in accordance 
with the European legislation on data protection.22  
Initial development of the questionnaire 
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The researchers developed the QoLAF-Q based on their experiences with patients, 
the most frequent clinical manifestations of anal fistulae,2 and the domains included in 
the WHOQOL.23 The initial version of the QoLAF-Q (i-QoLAF-Q) was developed in 
Spanish and comprised of 17 items, which response options followed a 5-point Likert-
type format.  
Before its administration to the study participants, the i-QoLAF-Q was critically 
revised by a panel of 14 independent experts in coloproctology and colorectal surgery 
from different institutions. In order to calculate the content validity index (CVI) of the i-
QoLAF-Q, these experts were requested to score each item as 1=‘not relevant’, 
2=‘somewhat relevant’, 3=‘quite relevant’ or 4=‘highly relevant’ for measuring QoL in 
patients diagnosed with AF.24 Each individual item’s CVI (I-CVI) was estimated by 
summing the number of experts rating the item as either ‘quite relevant’ or ‘highly 
relevant’ and dividing it by the total number of experts in the panel.24 For a panel of 14 
experts, an I-CVI≥0.78 is acceptable as it shows a high degree of agreement about its 
relevance.24 Table 1 shows that the experts considered items 3, 4 and 16 not to be 
relevant for measuring QoL in patients diagnosed with AF (I-CVI<0.78) and they were 
removed from the QoLAF-Q (see Appendix 1 for further information on the questions 
and response options for the QoLAF-Q). 
Data analysis of the final version of the QoLAF-Q 
The 14-item version of the QoLAF-Q was tested amongst the study sample and 
psychometrically evaluated following other authors’ guidelines and 
recommendations.24-28 The QoLAF-Q was originally developed and tested in Spanish. 
The forward-backward translation procedure recommended by the ‘European 
Organisation for Research and Treatment of Cancer’ was used to translate the QoLAF-
Q to English.29 IBM® SPSS® v.21 was used to perform the data analysis.  
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Readability and understandability 
The readability and grade level of the QoLAF-Q was assessed using the Flesch-
Kincaid tool in Microsoft Word®. To evaluate its understandability, ten independent 
native Spanish-speakers and five independent non-native, non-proficient Spanish-
speakers were asked to comment on the difficulties they might have found when reading 
and completing the QoLAF-Q. Using feedback from non-native, non-proficient 
Spanish-speakers can give directions to further simplify the readability of the tool and 
improve its understandability.25-26 The completion time for the instrument was recorded. 
Reliability 
To evaluate the reliability of the QoLAF-Q, its internal consistency and temporal 
stability were investigated. The internal consistency of the QoLAF-Q was evaluated 
using the following three estimators: [1] Cronbach’s coefficient alpha for the overall 
tool, [2] estimated Cronbach’s alpha of the overall tool if a particular item was 
removed, [3] corrected item-total correlation (C-ITC). Items were considered to 
positively contribute to increase the internal consistency of the QoLAF-Q if their item’s 
corrected C-ITC>0.3, and the tool’s Cronbach’s alpha coefficient did not significantly 
increase after removing that particular item. To assess the QoLAF-Q’s temporal 
stability, participants completed the questionnaire in two occasions separated by a 4-
week interval using an identical data collection procedure for the test and retest. The 
Spearman’s correlation coefficient (r) and the weighted Cohen’s kappa (k) were 
calculated. In this 4-week interval, participants underwent further diagnostic tests and 
did not receive any treatment; they were recommended to maintain good hygiene of the 
perianal area. 
Validity 
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The content, criterion and construct validity of the QoLAF-Q were examined. For 
the assessment of the QoLAF-Q’s content validity, the average CVI of the overall 
questionnaire (S-CVI/Ave) was calculated; the data obtained from the critical review 
procedure performed by the aforementioned panel of experts were used for its 
calculation. A S-CVI/Ave>0.90 was considered as evidence of the instrument’s content 
validity.24 For the assessment of the QoLAF-Q’s criterion validity, its concurrent 
validity was studied and the SF-12 Health-Survey (SF-12) was used as the criterion of 
reference for comparisons.30 The decision to use the SF-12 for comparisons was based 
on the following criteria: [1] it measures all the domains comprising the construct 
‘health-related QoL’,23,30 [2] it is a widely used instrument that has shown excellent 
psychometric properties in its Spanish version,30 and [3] it is short, easy to understand 
and simple to complete by the participants.  The Spearman’s correlation coefficient (r) 
between patients’ results on the QoLAF-Q and their results on the Spanish version of 
the SF-12 was calculated. Additionally, we conducted an ordinal logistic regression 
analysis in which the associations between the participants’ scores in the QoLAF-Q and 
the SF-12 were explored. Lastly, for the assessment of the QoLAF-Q’s construct 
validity, principal component analysis (PCA) and known-groups analysis were 
performed.  
PCA. This analysis aimed to identify the principal components of the QoLAF-Q and the 
items that should be retained as part of the instrument. Before investigating the structure 
of the QoLAF-Q, the appropriateness to perform PCA was tested by carrying out the 
Kaiser-Meyer-Olkin Measure of Sampling Adequacy and the Bartlett’s Test of 
Sphericity. Then, an unlimited factor analysis test with Varimax rotation was computed. 
Factors were retained as part of the QoLAF-Q if they met the following criteria: [1] 
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factors’ eigenvalues ≥1, [2] presence of a clear graphic representation of the factor on 
the plot of eigenvalues, and [3] its items’ factor-loading value ≥0.45.31 
Known-group analysis. The total sample (N=54) was divided in groups depending on 
the participants’ scores on the following clinical manifestations: frequency of 
suppuration, amount of suppuration, frequency of pain, and intensity of pain. Based on 
this categorisation, between-groups differences in individuals’ QoLAF-Q scores were 
expected and Kruskal-Wallis H Test was carried out to explore them. 
Development of a scoring and interpretation system for the QoLAF-Q 
Participants’ score on the QoLAF-Q could range from 14 (minimum score) to 70 
(maximum score). Using a summation method,32 the following five-category scoring 
and interpretation system was developed: ‘zero impact’=14 points, ‘limited impact’=15-
28 points,  ‘moderate impact’=29-42 points, ‘high impact’=43-56, and very ‘high 
impact’=57-70 points. 
A panel of 20 experts were asked to score their degree of agreement with the 
appropriateness and usefulness of the aforementioned scoring and interpretation system 
using a 5-point Likert scale (1=strongly agree, 2=agree, 3=neither agree or disagree, 
4=disagree, 5=strongly disagree). Furthermore, the experts were asked to provide any 
feedback they considered appropriate about the scoring and interpretation system 
proposed by the researchers. 
Results 
There were not any missing values in the dataset used in this study. 
Description of the main sample 
The main sample’s mean age was 46.7 years (SD=11.60; range=24-70) and it was 
comprised of 74.1% male participants. Table 2 presents detailed information about 
patients’ demographics, past medical history and specific characteristics of their AF. 
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Readability and understandability 
The reading level of the QoLAF-Q corresponds to 4th grade, so it can be read by a 
schooled ten-year-old individual. Neither the independent native Spanish-speakers, nor 
the independent non-native, non-proficient Spanish-speakers reported any difficulties 
when reading and completing the QoLAF-Q. Furthermore, mean completion time was 
less than 5 minutes (range=4-6 minutes). 
Reliability 
Table 1 presents detailed results of the internal consistency analysis for the 
QoLAF-Q (N=54). The QoLAF-Q’s Cronbach’s α=0.908, which would not have 
significantly increased after removing any of the items. The C-ITC for the items ranged 
from 0.35-0.83. Regarding the analysis of the tool’s temporal stability, the Spearman’s 
correlation coefficient between the test and the 4-week retest was very high (r=0.861; 
p<0.001). Additionally, the weighted Cohen’s kappa was very good when unequal 
distance between the response options was assumed (quadratic k=0.82; 95% CI=0.735-
0.906), and good when equal distance between the response options was assumed 
(linear k=0.72; 95% CI=0.593-0.847) (see Table 3). 
Validity 
Regarding content validity, the I-CVI for the 14 items comprising the QoLAF-Q 
ranged from 0.79-1 (see Table 1) and the QoLAF-Q’s S-CVI/Ave=0.92. In terms of 
concurrent validity, the QoLAF-Q showed a strong, significant correlation with the SF-
12 (r=0.734; p<0.001). Moreover, ordinal logistic regression analysis suggested that 
participants’ scores on the QoLAF-Q explained approximately 46.2% of the between-
subject variation for the participants’ scores on the SF-12 (Nagelkerke-R2=0.462). 
However, those patients in whom the AF has a limited or moderate impact over their 
QoL (based on their scores on the QoLAF-Q) had statistically significant higher odds of 
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scoring among the groups with worse health-related QoL (based on their results on the 
SF-12), with an odds ratio (OR) of 0.020 [95% CI=0.04-0.95] and an OR of 0.124 [95% 
CI=0.032-0.485], respectively (see Table 4 for a summary of the interactions between 
participants’ results on the SF-12 and the QoLAF-Q). Results for construct validity 
analysis are presented below. 
PCA 
The Barlett’s Test of Sphericity was significant (χ2=450.32; p<0.01) and the 
Kaiser-Meyer-Olkin measure of sampling adequacy was 0.764; thus, PCA was carried 
out. Table 5 presents the results of the PCA on the 14-item QoLAF-Q. Two factors 
showed eigenvalues ≥1, a clear graphic representation on the plot of eigenvalues, and all 
their loading items with a factor-loading coefficient ≥0.45. These two factors accounted 
for 81.63% of the total variance found and refer to the physical (Factor 1) and 
biopsychosocial (Factor 2) impact of the AF (see Table 5). 
Known-groups analysis 
Known-groups analysis results are shown in Table 6. In summary, the Kruskal-
Wallis H Test showed that the participants’ scores on the total QoLAF-Q and its two 
subscales are significantly different (p<0.05) depending on their self-reported frequency 
of suppuration, amount of suppuration, frequency of pain, and intensity of pain. 
Scoring and interpretation system for the QoLAF-Q 
The 20 experts revising the scoring and interpretation system proposed by the 
researchers either strongly agreed (n=17) or agreed (n=3) with its appropriateness. No 
further changes were required. 
Discussion 
Our literature review suggested that QoL is an essential indicator to be taken into 
consideration when deciding the strategy to be followed in the treatment of patients 
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diagnosed with AF.14-21 However, previously published studies exploring QoL amongst 
these patients have always used instruments that were initially designed for the 
evaluation of more generic populations’ QoL.16-21 To the best of our knowledge, no 
specific tools for the assessment of QoL in patients with AF have been previously 
designed, validated and published; hence why this study aimed to develop and evaluate 
the psychometric properties of the ‘Quality of Life in patients with Anal Fistula 
Questionnaire’ (QoLAF-Q). 
The psychometric evaluation of the QoLAF-Q intended to find an evidence-based 
answer to the following three questions: [1] does the tool measure accurately? [2] what 
does the tool actually measure? and [3] is the tool actually usable? Whilst questions one 
and two refer to the reliability and validity of the QoLAF-Q, question three concerns the 
tool’s readability, understandability and applicability.27-28 
Regarding the first question, the psychometric analysis performed demonstrated 
the excellent internal consistency and temporal stability of the QoLAF-Q among the 
study sample. These qualities could be considered proof of the tool’s reliability, 
repeatability and reproducibility.27-28 
In order to answer the second question, content, criterion and construct validity of 
the QoLAF-Q were explored. Firstly, the QoLAF-Q’s content validity analysis included 
a process of critical review by a panel of 14 experts and evidenced that all the items 
included in the final 14-item version of the QoLAF-Q contributed to the 
operationalization of ‘quality of life in patients with AF’ as a measurable concept.24,27-28 
Secondly, in relation to criterion validity, the QoLAF-Q’s concurrent validity was 
assessed by exploring its ability to correlate and converge with patients’ score on the 
SF-12, which measures individuals’ health-related QoL. Evidence has shown that the 
QoLAF-Q does not only correlate very strongly with this previously-validated and 
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widely-used tool, but is also able to make similar decisions about patients’ QoL. These 
results could be interpreted as an indicator of the QoLAF-Q’s ability to provide valid 
information about the QoL of patients diagnosed with AF.27-28 Furthermore, regarding 
the tool’s construct validity, evidence from the PCA suggests that the QoLAF-Q has 
two clearly-defined subscales, which evaluate the extent in which the AF impacts the 
patient’s physical and biopsychosocial domains of QoL. Corroborating the confirmatory 
evidence of the instrument’s construct validity, results from the known-group analysis 
showed the QoLAF-Q’s ability to detect expected differences between individuals 
depending on their symptomatology. 
Lastly, concerning the usability of the instrument, results have shown that the 
QoLAF-Q is an easily understandable and applicable tool which can be completed in 
less than 5 minutes and provide immediate information about the impact that the AF has 
on patients’ QoL. 
Although the QoLAF-Q could be used in research (e.g. experimental designs 
comparing the efficacy of different treatment approaches on patients’ QoL), and in 
clinical practice (e.g. as part of the initial assessment of patients with AF), some 
limitations must be highlighted. Firstly, the small size of the main sample, which could 
have affected the validity of our PCA and known-groups analysis, together with the use 
of a convenience sampling method does not allow for the generalisation of the results. 
As the participants were a relatively small group of patients with specific characteristics 
(for example, all patients presented with a cryptoglandular AF and the majority were 
males), those willing to use the QoLAF-Q amongst different populations should 
conduct a validation study before doing so. Secondly, although the participants were 
encouraged to make comments on how they would improve the QoLAF-Q once they 
had completed it, this study did not include them in the discussion that led to the initial 
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development of the questionnaire. We suggest that future validation and adaptation 
studies of the QoLAF-Q conduct in-depth interviews and/or focus groups in which 
patients have the opportunity to be more actively involved with the process of deciding 
which items are included in the questionnaire and how these items are worded. Thirdly, 
our scoring system for the QoLAF-Q does not take into account that some items may be 
more important than others for measuring the underlying construct and may potentially 
lead to a cancellation effect.32 We recommend that future studies develop scoring 
systems using other approaches and compare them to the one presented in this 
manuscript. Lastly, as the QoLAF-Q was created and psychometrically tested in 
Spanish, its use in other languages must be preceded by an appropriate translation and 
validation process. 
Conclusions 
The QoLAF-Q has shown excellent psychometric properties after being subjected 
to a rigorous testing process. The QoLAF-Q has proven to be a valid, reliable and 
concise tool that could contribute to the evaluation of quality of life amongst patients 
with anal fistula. Additionally, its easy and rapid applicability could facilitate its use and 
contribute to informing the physician in the decision-making process in which the most 
suitable treatment for each particular case is usually discussed. It is suggested that 
future studies focus on assessing the QoLAF-Q’s psychometric properties after 
translating it into different languages and validating its usability on larger randomised 
samples of patients. 
Acknowledgements 
The authors thank all the individuals who voluntarily participated in the study. 
References 
1. Marks CG, Ritchie JK. Anal fistulas at St Mark's Hospital. Br J Surg. 1977;64:84-91. 
	 15	
2. Vasilevsky CA, Gordon PH. Benign anorectal: abscess and fistula. In Wolff: The 
ASCRS Textbook of Colon and Rectal Surgery. 3rd Edition. Cleveland, 
USA:Springer; 2016. 
3. Sainio P. Fistula-in-ano in a defined population. Incidence and epidemiological 
aspects. Ann Chir Gynaecol. 1984;73:219-224. 
4. Zanotti C, Martinez-Puente C, Pascual I, Pascual M, Herreros D, García-Olmo D. An 
assessment of the incidence of fistula-in-ano in four countries of the European 
Union. Int J Colorectal Dis. 2007;22:1459-1462.  
5. Jacob TJ, Perakath B, Keighley MR. Surgical intervention for anorectal fistula. 
Cochrane Database Syst Rev. 2010;12:CD006319.  
6. Abcarian H. Anorectal infection: abscess-fistula. Clin Colon Rectal Surg. 2011;24: 
14-21.  
7. Shouler PJ, Grimley RP, Keighley MR, Alexander-Williams J. Fistula-in-ano is 
usually simple to manage surgically. Int J Colorectal Dis. 1986;1:113-115. 
8. Fisher OM, Raptis DA, Vetter D, et al. An outcome and cost analysis of anal fistula 
plug insertion vs endorectal advancement flap for complex anal fistulae. Colorectal 
Dis. 2015;17:619-626. 
9. Blumetti J, Abcarian A, Quinteros F, Chaudhry V, Prasad L, Abcarian H. Evolution 
of treatment of fistula in ano. World J Surg. 2012;36:1162-1167. 
10. Steele SR, Kumar R, Feingold DL, Rafferty JL, Buie WD. Standards Practice Task 
Force of the American Society of Colon and Rectal Surgeons. Practice parameters 
for the management of perianal abscess and fistula-in-ano. Dis Colon Rectum. 
2011;54:1465–1474. 
11. Narang SK, Keogh K, Alam NN, Pathak S, Daniels IR, Smart NJ. A systematic 
review of new treatments for cryptoglandular fistula in ano. Surgeon. 2017;15:30-39. 
	 16	
12. Bubbers EJ, Cologne KG. Management of Complex Anal Fistulas. Clin 
Colon Rectal Surg. 2016;29:43-49. 
13. Göttgens KW, Smeets RR, Stassen LP, Beets G, Breukink SO. 
Systematic review and metaanalysis of surgical interventions for high cryptoglandula
r perianal fistula. Int J Colorectal Dis. 2015;30:583-593. 
14. Malik AI, Nelson RL. Surgical management of anal fistulae: a systematic review. 
Colorectal Dis. 2008;10:420-430.  
15. Visscher AP, Schuur D, Slooff RA, Meijerink WJ, Deen-Molenaar CB, Felt-Bersma 
RJ. Predictive factors for recurrence of cryptoglandular fistulae characterized by 
preoperative three-dimensional endoanal ultrasound. Colorectal Dis. 2016;18:503-
509.  
16. Owen HA, Buchanan GN, Schizas A, Cohen R, Williams AB. Quality of life with 
anal fistula. Ann R Coll Surg Engl. 2016;98:334-338. 
17. Riss S, Schwameis K, Mittlböck M, et al. Sexual function and quality of life after 
surgical treatment for anal fistulas in Crohn's disease. Tech Coloproctol. 2013;17:89-
94.  
18. Kristo I, Stift A, Staud C, et al. The type of loose seton for complex anal fistula is 
essential to improve perianal comfort and quality of life. Colorectal 
Dis. 2016;18:194-198. 
19. Kasparek MS, Glatzle J, Temeltcheva T, Mueller MH, Koenigsrainer A, Kreis ME. 
Long-term quality of life in patients with Crohn's disease and perianal fistulas: 
influence of fecal diversion. Dis Colon Rectum. 2007;50:2067-2074. 
20. Visscher AP, Schuur D, Roos R, Van der Mijnsbrugge GJ, Meijerink WJ, Felt-
Bersma RJ. Long-term follow-up after surgery for simple and complex 
	 17	
cryptoglandular fistulas: fecal incontinence and impact on quality of life. Dis Colon 
Rectum. 2015;58:533-539.  
21. Mylonakis E, Katsios C, Godevenos D, Nousias B, Kappas AM. Quality of life of 
patients after surgical treatment of anal fistula; the role of anal manometry. 
Colorectal Dis. 2001;3:417-21. 
22. Directive 95/46/EC of the European Parliament and of the Council of 24th of 
October 1995 on the protection of individuals with regard to the processing of 
personal data and on the free movement of such data. Official Journal of the 
European Communities L 281/31, 23.10.1995, p. 31-39. 
23. Skevington SM, Lotfy M, O'Connell KA, WHOQOL Group. The World Health 
Organization's WHOQOL-BREF quality of life assessment: psychometric properties 
and results of the international field trial. A report from the WHOQOL group. Qual 
Life Res. 2004;13:299-310. 
24. Polit  DF, Beck CT. The content validity index: are you sure you know what’s being 
reported? Critique and recommendations. Research in Nursing & Health. 
2006;29:489-497. 
25. Hernández-Padilla J, Suthers F, Fernández-Sola C, Granero-Molina J. Development 
and psychometric assessment of the basic resuscitation skills self-efficacy scale. Eur 
J Cardiovasc Nurs. 2016;15:e10-e18.  
26. Hernández-Padilla JM, Granero-Molina J, Márquez-Hernández VV, Suthers F, 
Fernández-Sola C. Development and psychometric evaluation of the arterial puncture 
self-efficacy scale. Nurse Educ Today. 2016;40:45-51.  
27. Coaley K. An introduction to psychological assessment and psychometrics. London, 
UK: SAGE; 2014. 
28. Furr RM. Psychometrics: an introduction. London, UK: SAGE; 2014. 
	 18	
29. Koller M, Aaronson NK, Blazeby J, et al. Translation procedures for standardized 
quality of life questionnaires: The European Organisation for Research and 
Treatment of Cancer (EORTC) approach. Eur J Cancer. 2007;43:1810-1820. 
30. Vilagut G, Valderas JM, Ferrer M, Garin O, López-García E, Alonso J. 
Interpretation of SF-36 and SF-12 questionnaires in Spain: physical and mental 
components. Med Clin. 2008;130:726-735. 
31. Tabachnick BG, Fidell LS. Using Multivariate Statistics. 6th ed.  Essex, UK: 
Pearson; 2013. 
32. Avila ML, Stinson J, Kiss A, Brandão LR, Uleryk E, Feldman BM. A critical 
review of scoring options for clinical measurement tools. BMC Research Notes. 
2015;8:612. 
	 19	
 
Table 1.  
Results of the content validity (N=14) and internal consistency analysis of the QoLAF-Q (N=54). 
  
 
I-CVI† 
QoLAF-Q’s 
Cronbach alpha if 
ítem deleted 
Corrected ITC‡ 
1. How often do you experience discharge (suppuration) 
from the fistula? 
.93 .910 .42 
2. How much discharge (suppuration) from the fistula do 
you experience? 
.93 .910 .35 
3. How often do you bleed from the fistula? .21 
Removed from QoLAF-Q before testing it with 
patients  (I-CVI<0.78) 
4. How much bleeding from the fistula do you experience? .14 
Removed from QoLAF-Q before testing it with 
patients  (I-CVI<0.78) 
5. How often do you experience uncontrollable flatulence 
(farting) since having the fistula? 1 
.908 .44 
6. How often do you experience unintentional loss of stools 
since having the fistula? 1 
.907 .44 
7. What is the amount of unintentional stool loss that you 
usually experience since having the fistula? .93 
.908 .40 
8. How often do you experience pain in the anal area as a 
consequence of the fistula? 
.93 .897 .72 
9. What is the intensity of the pain that you experience as a 
consequence of the anal fistula? 
.86 .902 .59 
10. Since suffering the symptoms of the anal fistula, how 
would you say your health is? 
1 .901 .64 
11. How much does the anal fistula affect your physical 
health? (e.g. energy and activity levels, sleeping pattern, 
general well-being…) 
.86 .892 .81 
12. How much does the anal fistula affect your psychological 
health? (e.g. your body image, self-esteem, state of mind, 
ability to focus on a particular task…) 
.93 .896 .73 
13. How much does the anal fistula affect your independence 
level? (e.g. mobility, ability to work, daily activities…) 
.86 .897 .71 
14. How much does the anal fistula affect your social 
relationships and interactions with others? (e.g. your 
relationships with friends, family, partner…) 
.93 .893 .80 
15. How much does the anal fistula affect your sexual 
relationships? 
.93 .898 .69 
16. How much does the anal fistula affect your beliefs, values 
and attitudes? (e.g. your religious practices, your eating 
and drinking practices, your general beliefs…) 
.29 
Removed from QoLAF-Q before testing it with 
patients  (I-CVI<0.78) 
17. How much does the anal fistula affect other aspects of 
your life? (e.g. your freedom, your economic income, 
your free time…) 
.79 .891 .83 
† I-CVI = Item Content Validity Index 
‡ ITC = Item-total Correlation 
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Table 2. 
Demographic characteristics of main sample 
 
 
Main Sample 
(N=54) 
 M ± S.D. 
Age (years) 46.9 ± 11.60 
 n (%) 
Gender  
Female 14 (25.9) 
Male 40 (74.1) 
Comorbidities  
Hypertension 12 (22.2) 
Diabetes Mellitus Type I 3 (5.6) 
Diabetes Mellitus Type II 4 (7.4) 
Obstetric damage  
Yes 0 (0) 
No 54 (100) 
Previous anal surgery  
No previous anal surgery 17 (31.5) 
One previous anal surgery 15 (27.8) 
More than one anal surgery 22 (40.7) 
Clinical manifestations  
Suppuration 45 (83.3) 
Bleeding 26 (48.1) 
Pain 31 (57.4) 
Incontinence 0 (0) 
Main symptomatology  
Suppuration 38 (70.4) 
Bleeding 3 (5.6) 
Pain 13 (24.1) 
Incontinence 0 (0) 
	 21	
Location of EFO  (based on physical anamnesis*) 
Unidentified EFO 0 (0) 
Anterior 8 (14.8) 
Posterior 14 (25.9) 
Right lateral 18 (33.3) 
Left lateral 14 (25.9) 
Location of IFO (based on digital rectal examination*) 
Unidentified IFO 25 (46.3) 
Anterior 7 (13.0) 
Posterior 15 (27.8) 
Right lateral 5 (9.3) 
Left lateral 2 (3.7) 
Type of anal fistula (based on findings from physical anamnesis*, 
and/or digital rectal examination*, and/or injection of hydrogen 
peroxide + saline solution*, and/or MRI**, and/or anoscopy**) 
Intersphincteric 18 (33.3) 
Transsphincteric 27 (50) 
Suprasphincteric 0 (0) 
Extrasphincteric 3 (5.6) 
Undetermined 6 (11.1) 
* The physical anamnesis, the digital rectal examination and the 
injection of hydrogen peroxide were performed during the patients’ 
visit to the outpatient coloproctology clinic. 
** The MRI and anoscopy were requested in order to confirm 
diagnosis of the anal fistula and determine its classification after the 
first visit to the outpatient coloproctology clinic. 
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Table 3. 
Results of the weighted Cohen’s kappa analysis for the assessment of the QoLAF-Q’s temporal 
stability at 4-week retest (N=54).1 
 
 
 
Impact of the anal fistula on the participants’ QoL at initial test (N=54) 
Relative 
frequency 
n/N (%) 
Zero Impact 
Frequency (n) 
Limited 
Impact 
Frequency (n) 
Moderate 
Impact 
Frequency (n) 
High Impact 
Frequency (n) 
Very High 
Impact 
Frequency (n) 
Im
pa
ct
 o
f t
he
 a
na
l f
is
tu
la
 o
n 
th
e 
pa
rt
ic
ip
an
ts
’ Q
oL
 a
t 4
-
w
ee
k 
re
-t
es
t (
N
=5
4)
 
Zero impact  
Frequency (n) 
0 0 0 0 0 0/0 (0%) 
Limited impact 
Frequency (n) 
0 16 2 0 0 18/54 
(33.3%) 
Moderate Impact 
Frequency (n) 
0 4 12 2 0 18/54 
(33.3%) 
High Impact 
Frequency (n) 
0 0 4 12 2 18/54 
(33.3%) 
Very High Impact 
Frequency (n) 
0 0 0 0 0 0/0 (0%) 
Relative frequency 
n/N (%) 
0/0 (0%) 20/54 (37%) 18/54 (33.3%) 14/54 (25.9%) 2/54 (3.7%) 54/54 
(100%) 
       
 
Equal distance between response options assumed 
(Linear weighted Cohen’s kappa) 
Unequal distance between response options assumed 
(Quadratic weighted Cohen’s kappa) 
Weighted kappa (k)  0.720 0.821 
Standard error 0.065 0.044 
95% CI 0.593 – 0.847 0.735 – 0.906 
1Categorisation was made on the basis of participants’ scores on the QoLAF-Q following the scoring system 
presented in this manuscript. 
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Table 4. 
Simplified summary of the interactions between participants’ scores on the QoLAF-Q and SF-12. (N=54) 
  
 
Participants’ general health-related QoL1 
(N=54) 
  Very good 
health-related 
QoL 
(n=15) 
Good health-
related QoL 
(n=10) 
Fair health-
related QoL 
(n=15) 
Poor health-
related QoL 
(n=12) 
Very poor 
health-related 
QoL 
(n=2) 
Im
pa
ct
 o
f t
he
 a
na
l f
is
tu
la
 o
n 
th
e 
pa
rt
ic
ip
an
ts
’ Q
oL
2  
(N
=5
4)
 
Zero impact 
(n=0) 
0 0 0 0 0 
Limited impact 
(n=20) 
11 5 4 0 0 
Moderate impact 
(n=17) 
4 4 5 4 0 
High impact 
(n=15) 
0 1 6 6 2 
Very high impact 
(n=2) 
0 0 0 2 0 
1Health-related QoL categorisation was made on the basis of participants’ scores on the SF-12 Health-
Survey. 
2Impact of the anal fistula on the patient’s QoL was categorised according to the scoring system proposed in this 
manuscript. 
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Table 5. 
Factor loadings and total variance explained from the rotated factor 
structure of the QoLAF-Q (N=54). 
Item by Factor Factor 
1 2 
Physical impact of the anal fistula 
1. How often do you experience discharge (suppuration) from the 
fistula? .671 
 
2. How much discharge (suppuration) from the fistula do you 
experience? .628 
 
3. How often do you experience uncontrollable flatulence (farting) since 
having the fistula? .484 
 
4. How often do you experience unintentional loss of stools since having 
the fistula? .784 
 
5. What is the amount of unintentional stool loss that you usually 
experience since having the fistula? .754 
 
6. How often do you experience pain in the anal area as a consequence 
of the fistula? .757 
 
7. What is the intensity of the pain that you experience as a consequence 
of the anal fistula? .676 
 
Biopsychosocial impact of the anal fistula   
8. Since suffering the symptoms of the anal fistula, how would you say 
your health is? 
 .636 
9. How much does the anal fistula affect your physical health? (e.g. 
energy and activity levels, sleeping pattern, general well-being…) 
 .672 
10. How much does the anal fistula affect your psychological health? (e.g. 
your body image, self-esteem, state of mind, ability to focus on a 
particular task…) 
 .644 
11. How much does the anal fistula affect your independence level? (e.g. 
mobility, ability to work, daily activities…) 
 .653 
12. How much does the anal fistula affect your social relationships and 
interactions with others? (e.g. your relationships with friends, family, 
partner…) 
 .649 
13. How much does the anal fistula affect your sexual relationships? 
 .672 
14. How much does the anal fistula affect other aspects of your life? (e.g. 
your freedom, your economic income, your free time…) 
 .637 
% of variance 45.16 36.47 
Cumulative % of variance 45.16 81.63 
	
	
	
 
Table 6. 
Results of the known-groups analysis.1 (N=54) 
 Frequency of suppuration Amount of suppuration Frequency of pain Intensity of pain 
 Never or 
rarely 
(n=14) 
Sometimes 
(n=9) 
Very often 
or always 
(n=31) 
Between-
groups 
differences2 
None or 
limited 
(n=23) 
Moderate 
(n=16) 
High or 
very high 
(n=15) 
Between-
groups 
differences2 
Never or 
rarely 
(n=20) 
Sometimes 
(n=9) 
Very often 
or always 
(n=25) 
Between-
groups 
differences2 
None or 
limited 
(n=17) 
Moderate 
(n=24) 
High or 
very high 
(n=13) 
Between-
groups 
differences2 
 Mean Rank Mean Rank Mean Rank p-value3 Mean Rank Mean Rank Mean Rank p-value3 Mean Rank Mean Rank Mean Rank p-value3 Mean Rank Mean Rank Mean Rank p-value3 
Physical impact  14.82 24.44 34.11 <0.001 20.54 31.56 33.83 0.009 13.13 32.50 37.20 <0.001 15.00 28.54 41.92 <0.001 
Biopsychological 
impact 20.36 20.83 32.66 0.015 22.59 29.44 32.97 0.048 15.80 25.61 37.54 <0.001 16.56 28.65 39.69 <0.001 
Total QoLAF-Q 17.21 21.56 33.89 <0.001 22.02 28.63 34.70 0.034 14.00 25.50 39.02 <0.001 14.79 29.75 39.96 <0.001 
1Known-groups categorisation was made on the basis of participants’ self-reported suppuration (frequency and amount) and pain (frequency and intensity). 
2Between-groups differences were analysed using Kruskal-Wallis H Test. 
3Significance level when p-value≤0.05 	
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Código	de	
identificación	
	
	 Iniciales	del	paciente	(si	el	paciente	acepta)	 	
Edad	 	 Nivel	de	estudios	 	
Sexo	 	 Fecha	 	 	
Ingresos	familiares	
medios	(euros/mes)	 	 	
	
Cuestionario	de	calidad	de	vida	en	pacientes	con	
fistula	anal	(QoLAF-Q)©		Hemos	 creado	 este	 cuestionario	 con	 la	 intención	 de	 conocer	mejor	 cómo	 afecta	 la	fistula	anal	en	su	calidad	de	vida.	Como	puede	 ver	más	 abajo,	 cada	pregunta	 tiene	 cinco	 opciones	de	 respuesta.	 Cada	una	de	estas	opciones	ha	sido	numerada	del	1	al	5.	Para	responder	a	cada	pregunta	solo	tiene	que	redondear	el	número	correspondiente	a	la	respuesta	que	quiere	dar.	Si	lo	prefiere,	puede	marcar	con	una	cruz	la	casilla	que	encontrará	al	lado	de	cada	número.	Si	 tiene	 alguna	 duda	 o	 necesita	 ayuda	 para	 rellenar	 este	 cuestionario,	 no	 dude	 en	preguntar	a	su	médico	y	este	le	ayudará	encantado.	Por	último,	recuerde	que	su	información	será	tratada	con	total	confidencialidad.		
1.	 ¿Con	qué	frecuencia	le	sale	pus	de	la	fístula	anal?	1	 	 2	 	 3	 	 4	 	 5	 	Nunca	 Rara	vez	(pasan	semanas	sin	que	supure)	 A	veces	o	de	vez	en	cuando	(alguna	vez	todas	las	semanas)	
Frecuentemente	(casi	todos	los	días)	 Siempre	o	de	manera	continua	(todos	los	días)	
	
2.	 ¿Qué	cantidad	de	pus	le	sale	de	la	fístula?	1	 	 2	 	 3	 	 4	 	 5	 	Nada Escasa	(mancho	ligeramente	la	ropa	interior)	 Moderada		(mancho	bastante	la	ropa	interior	y	necesito	1	gasa	diaria)	 Alta		(tengo	que	usar	varias	gasas	simultáneamente	o	una	compresa	diaria)	
Extrema	(tengo	que	usar	más	de	4	compresas	o	paquetes	de	gasas	diarias) 
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3.	 ¿Con	que	frecuencia	se	le	escapan	gases	desde	que	tiene	la	fístula?	1	 	 2	 	 3	 	 4	 	 5	 	Nunca	 Rara	vez	(pasan	semanas	sin	que	me	pase)	 A	veces	o	de	vez	en	cuando	(alguna	vez	todas	las	semanas)	
Frecuentemente	(casi	todos	los	días)	 Siempre	o	de	manera	continua	(todos	los	días)	
	
4.	 ¿	Con	que	frecuencia	se	le	escapan	heces	desde	que	tiene	la	fístula?	1	 	 2	 	 3	 	 4	 	 5	 	Nunca Rara	vez	(pasan	semanas	sin	que	me	pase)	 A	veces	o	de	vez	en	cuando	(alguna	vez	todas	las	semanas)	
Frecuentemente	(casi	todos	los	días)	 Siempre	o	de	manera	continua	(todos	los	días)	
	
5.	 ¿Qué	cantidad	de	heces	se	le	escapa	desde	que	tiene	la	fístula?	1	 	 2	 	 3	 	 4	 	 5	 	Nada	 Escasa	(mancho	ligeramente	la	ropa	interior)	 Moderada		(mancho	bastante	la	ropa	interior	y	necesito	1	gasa	diaria)	
Alta		(tengo	que	usar	varias	gasas	a	la	vez	o	una	compresa	diaria)	
Extrema	(tengo	que	usar	más	de	4	compresas	o	paquetes	de	gasas	diarias) 
	
6.	 ¿Con	qué	frecuencia	le	duele	la	zona	de	la	fístula?	1	 	 2	 	 3	 	 4	 	 5	 	Nunca	 Rara	vez	(pasan	semanas	sin	que	me	duela)	 A	veces	o	de	vez	en	cuando	(alguna	vez	todas	las	semanas)	
Frecuentemente	(casi	todos	los	días)	 Siempre	o	de	manera	continua	(todos	los	días) 
	
7.	 ¿Cuál	es	la	intensidad	del	dolor	que	le	provoca	la	fístula?	1	 	 2	 	 3	 	 4	 	 5	 	Nada	 Escaso		 Moderado		 Alto		 Extremo	o	el	peor	imaginable	
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8.	 Desde	que	sufre	los	síntomas	que	le	provoca	la	fístula,	¿cómo	diría	que	es	su	salud?	1	 	 2	 	 3	 	 4	 	 5	 	Excelente	 Buena	 Regular	o	aceptable	 Mala	 Horrible	
	
9.	 ¿Cuánto	afecta	la	fistula	anal	a	su	salud	física?	(por	ejemplo:	a	su	nivel	de	energía,	patrón	de	sueño,	bienestar	general…).	1	 	 2	 	 3	 	 4	 	 5	 	Nada	 Poco	 Ni	poco	ni	mucho	 Bastante	 Mucho	
	
10.	
Por	favor,	díganos	cuánto	afecta	la	fistula	a	su	salud	psicológica	(por	ejemplo:	a	su	imagen	corporal,	su	estado	de	ánimo,	su	autoestima,	su	capacidad	de	concentración…).	1	 	 2	 	 3	 	 4	 	 5	 	Nada	 Poco	 Ni	poco	ni	mucho	 Bastante	 Mucho 
	
11.	 ¿Cuánto	afecta	la	fistula	anal	a	su	nivel	de	independencia?	(por	ejemplo:	a	su	movilidad,	a	su	capacidad	de	trabajar,	a	sus	actividades	de	la	vida	diaria…).	1	 	 2	 	 3	 	 4	 	 5	 	Nada Poco	 Ni	poco	ni	mucho	 Bastante	 Mucho 
	
12.	 ¿Cuánto	afecta	la	fistula	anal	a	sus	relaciones	sociales?	(por	ejemplo:	a	sus	relaciones	con	amigos/pareja/familia…).	1	 	 2	 	 3	 	 4	 	 5	 	Nada	 Poco	 Ni	poco	ni	mucho	 Bastante	 Mucho	
	
13.	 ¿Cuánto	afecta	la	fistula	anal	a	sus	relaciones	sexuales?	1	 	 2	 	 3	 	 4	 	 5	 	Nada	 Poco	 Ni	poco	ni	mucho	 Bastante	 Mucho	
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14.	 ¿Cuánto	afecta	la	fistula	anal	a	otros	aspectos	de	su	vida?	(por	ejemplo:	a	su	libertad,	a	su	tiempo	libre,	a	sus	recursos	económicos…).	1	 	 2	 	 3	 	 4	 	 5	 	Nada	 Poco	 Ni	poco	ni	mucho	 Bastante	 Mucho	
	Por	favor	use	el	siguiente	recuadro	para	añadir	cualquier	comentario	que	desee	sobre	el	cuestionario.	
Gracias	por	su	colaboración.		
©	Este	 cuestionario	es	propiedad	 intelectual	 registrada.	Aquellas	personas	o	entidades	interesadas	en	su	uso	o	reproducción	(total	o	parcial)	deberán	solicitar	el	permiso	de	 los	autores.	Para	ello	podrán	contactar	con:		 									Este	 cuestionario	 ha	 sido	 elaborado	 con	 la	 inestimable	 colaboración	 de:	 José	 María	 Enríquez-Navascués,	 Eloy	 Espín-Basany,	 Fernando	 de	 la	Portilla	 de	 Juan,	 Francisco	 Blanco-Antona,	 Fernando	 Jiménez-Escovar,	 Lucinda	 Pérez-Domínguez,	 Matteo	 Frasson,	 Mario	 de	 Miguel-Velasco,	Natalia	Uribe-Quintana,	Héctor	Ortiz-Hurtado,	 Javier	Cerdán-Miguel,	Eduardo	Targarona-Soler,	Antonio	Codina-Cazador,	 Juan	García-Armengol,	José	Vicente	Roig-Vila,	Blas	Flor-Lorente,	María	Dolores	Frutos-Bernal,	José	Manuel	Ramírez-Rodríguez,	Vicente	Aguilella-Diago,	Antonio	Arroyo-Sebastián,	Antonio	Álvarez-García,	Isabel	Blesa-Sierra,	Ricardo	Belda-Lozano,	Elisabet	Vidaña-Márquez,	Jaime	Jorge-Cerrudo,	Francisco	Rubio-Gil,	Enrique	Herrera-Alonso,	y	Rafael	Rosado-Cobián.	
	
	
Manuel	Ferrer-Márquez	manuferrer78@hotmail.com	
José	Manuel	Hernández-Padilla	jm.hernandezpadilla@gmail.com		
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Participant’s	code	
	
	 Participants’	initial	(if	willing	to	share	them)		 	
Age	 	 Educational	level	 	
Gender	 	 Date	 	 	
Family	income	(net	per	month)	 	 	
	
Quality	of	Life	in	patients	with	Anal	Fistula	
Questionnaire	(QoLAF-Q)©		We	have	created	this	questionnaire	to	better	understand	how	your	anal	fistula	affects	your	quality	of	life.	As	 you	 can	 see	 below,	 each	question	we	 ask	has	 5	 possible	 response-options.	 Each	one	of	these	options	has	been	numbered	from	1	to	5.	In	 order	 to	 respond	 to	 each	 question	 you	 only	 need	 to	 circle	 the	 number	 that	corresponds	with	the	answer	you	want	to	give.	You	can	also	tick	the	box	next	to	the	number	if	you	prefer	doing	so.	If	you	have	got	any	questions,	do	not	understand	something	or	need	help	to	complete	this	questionnaire,	please	do	not	hesitate	to	ask	your	doctor.	He	will	happily	help	you.	Lastly,	please	remember	that	the	information	you	provide	us	will	be	treated	with	the	strictest	confidentiality.	 	
1.	 How	often	do	you	experience	discharge	(suppuration)	from	the	fistula?	1	 	 2	 	 3	 	 4	 	 5	 	Never	 Rarely	(Weeks	go	by	without	having	any	discharge)	 Sometimes	(I	have	some	discharge	every	week)	 Often	(I	have	discharge	almost	every	day)	 Always	or	continuously	(I	have	discharge	every	day)	
	
2.	 How	much	discharge	(suppuration)	from	the	fistula	do	you	experience?	1	 	 2	 	 3	 	 4	 	 5	 	None Limited	(I	very	slightly	stain	my	underwear)	 Some		(I	get	visible	stains	on	my	underwear)	 Quite	a	lot		(I	have	to	use	sanitary	towels)	 An	extreme	amount	(I	have	to	use	sanitary	towels	and	change	them	various	times	a	day) 
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3.	 How	often	do	you	experience	uncontrollable	flatulence	(farting)	since	having	the	fistula?	1	 	 2	 	 3	 	 4	 	 5	 	Never	 Rarely	(Weeks	go	by	without	having	any	uncontrollable	flatulence)	
Sometimes	(I	have	some	uncontrollable	flatulence	every	week)	
Often	(I	have	uncontrollable	flatulence	almost	every	day)	
Always	or	continuously	(I	have	uncontrollable	flatulence	every	day)	
	
4.	 How	often	do	you	experience	an	unintentional	loss	of	stools	since	having	the	fistula?	1	 	 2	 	 3	 	 4	 	 5	 	Never Rarely	(Weeks	go	by	without	having	any	unintentional	loss	of	stools)	
Sometimes	(I	have	some	unintentional	loss	of	stools	every	week)	
Often	(I	have	unintentional	loss	of	stools	almost	every	day)	
Always	or	continuously	(I	have	unintentional	loss	of	stools	every	day)	
	
5.	 What	is	the	amount	of	unintentional	stool	loss	that	you	usually	experience	since	having	the	fistula?	1	 	 2	 	 3	 	 4	 	 5	 	None	 Limited	(I	very	slightly	stain	my	underwear)	 Some		(I	get	visible	stains	on	my	underwear)	 Quite	a	lot		(I	have	to	use	sanitary	towels)	 An	extreme	amount	(I	have	to	use	sanitary	towels	and	change	them	various	times	a	day) 
	
6.	 How	often	do	you	experience	pain	in	the	anal	area	as	a	consequence	of	the	fistula?	1	 	 2	 	 3	 	 4	 	 5	 	Never	 Rarely	(Weeks	go	by	without	experiencing	any	pain)	 Sometimes	(I	experience	some	pain	every	week)	 Often	(I	experience	pain	almost	every	day)	 Always	or	continuously	(I	experience	pain	every	day) 
	
7.	 What	is	the	intensity	of	the	pain	that	you	experience	as	a	consequence	of	the	anal	fistula?	1	 	 2	 	 3	 	 4	 	 5	 	No	pain	 Mild	pain		 Moderate	pain		 Severe	pain		 Extreme	or	the	worst	imaginable	pain	
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8.	 Since	suffering	the	symptoms	of	the	anal	fistula,	how	would	you	say	your	health	is?	1	 	 2	 	 3	 	 4	 	 5	 	Excellent	 Good	 Acceptable	(it	is	not	too	bad)	 Bad	 Horrible	
	
9.	 How	much	does	the	anal	fistula	affect	your	physical	health?	(e.g.	energy	and	activity	levels,	sleeping	pattern,	general	well-being…)	1	 	 2	 	 3	 	 4	 	 5	 	Not	much	 Little	 Somewhat	 Much		 A	great	deal	
	
10.	 How	much	does	the	anal	fistula	affect	your	psychological	health?	(e.g.	your	body	image,	self-esteem,	state	of	mind,	ability	to	focus	on	a	particular	task…)	1	 	 2	 	 3	 	 4	 	 5	 	Not	much	 Little	 Somewhat	 Much		 A	great	deal 
	
11.	 How	much	does	the	anal	fistula	affect	your	independence	level?	(e.g.	mobility,	ability	to	work,	daily	life	activities…)	1	 	 2	 	 3	 	 4	 	 5	 	Not	much Little	 Somewhat	 Much		 A	great	deal 
	
12.	 How	much	does	the	anal	fistula	affect	your	social	relationships	and	interactions	with	others?	(e.g.	your	relationships	with	friends,	family,	partner…)	1	 	 2	 	 3	 	 4	 	 5	 	Not	much	 Little	 Somewhat	 Much		 A	great	deal	
	
13.	 How	much	does	the	anal	fistula	affect	your	sexual	relationships?	1	 	 2	 	 3	 	 4	 	 5	 	Not	much	 Little	 Somewhat	 Much		 A	great	deal	
	
14.	 How	much	does	the	anal	fistula	affect	other	aspects	of	your	life?	(e.g.	your	freedom,	your	economic	income,	your	free	time…)	1	 	 2	 	 3	 	 4	 	 5	 	Not	much	 Little	 Somewhat	 Much		 A	great	deal	
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	Please,	use	the	box	below	to	add	any	comments	you	wish	about	this	questionnaire.	
	Thanks	for	your	cooperation.		
©	 This	 questionnaire	 is	 copyrighted.	 Those	 individuals	 or	 organisations	 interested	 in	 using	 or	reproducing	the	QoLAF-Q	(totally	or	partially)	will	have	to	seek	permission	from	the	following	authors:			 										This	 questionnaire	 has	 been	 developed	with	 the	 expert	 collaboration	 of:	 José	María	 Enríquez-Navascués,	 Eloy	 Espín-Basany,	 Fernando	 de	 la	Portilla	 de	 Juan,	 Francisco	 Blanco-Antona,	 Fernando	 Jiménez-Escovar,	 Lucinda	 Pérez-Domínguez,	 Matteo	 Frasson,	 Mario	 de	 Miguel-Velasco,	Natalia	Uribe-Quintana,	Héctor	Ortiz-Hurtado,	 Javier	Cerdán-Miguel,	Eduardo	Targarona-Soler,	Antonio	Codina-Cazador,	 Juan	García-Armengol,	José	Vicente	Roig-Vila,	Blas	Flor-Lorente,	María	Dolores	Frutos-Bernal,	José	Manuel	Ramírez-Rodríguez,	Vicente	Aguilella-Diago,	Antonio	Arroyo-Sebastián,	Antonio	Álvarez-García,	Isabel	Blesa-Sierra,	Ricardo	Belda-Lozano,	Elisabet	Vidaña-Márquez,	Jaime	Jorge-Cerrudo,	Francisco	Rubio-Gil,	Enrique	Herrera-Alonso,	y	Rafael	Rosado-Cobián.	
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